Moderna's board amended bylaws to require federal court for Securities Act lawsuits, aligning with Delaware law. The FDA set a June 18 advisory panel for its mRNA flu vaccine after a filing setback. Insider share sales continue under a preset plan, while pediatric COVID vaccine effectiveness data emerged. These developments raise questions about the company's cash burn and path to profitability.